ACADIA Pharmaceuticals Inc. (ACAD) Institutional Ownership & Insider Trading

352 institutions reported holding ACADIA Pharmaceuticals Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 24 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ACADACADIA Pharmaceuticals Inc.Follow ACAD — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 3.4B
P/E TTM: 8.8
Dividend yield: —
52-week: —
Next earnings: 11 Nov, in 18 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

352 institutions held 97.9% of the shares. Across filers that reported both quarters, shares held changed +1.2%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	352	169	+1.2%	128	34	106	27
Mar 26	338	165	+0.1%	105	30	122	28
Dec 25	330	166	-2.4%	115	30	106	37
Sep 25	325	168	0.0%	112	48	95	21
Jun 25	305	171	-1.3%	83	38	119	45
Mar 25	314	171	+6.2%	93	53	95	31
Dec 24	292	163	+4.1%	103	53	67	25
Sep 24	255	155	-5.5%	84	28	72	40

ACADIA Pharmaceuticals Inc. — questions

Who owns ACADIA Pharmaceuticals Inc. stock?: 352 institutions reported ACADIA Pharmaceuticals Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BAKER BROS. ADVISORS LP (24.9%), BlackRock, Inc. (13.1%), STATE STREET CORP (5.3%).
Are ACADIA Pharmaceuticals Inc. insiders buying or selling?: 24 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from ACADIA Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.